Spin-Off

Riding high on record 2025 results and a new FDA approval, LivaNova faces intense scrutiny ahead of its May 6 earnings call. Can it sustain the momentum?

For 45 years, one program has quietly built global bridges in American living rooms. This is the story of how human connection defies global division.

Capstone Holding Corp. merges Midwest operations, targeting positive EBITDA by 2026 amid major project wins and a disciplined cost-cutting campaign.

A groundbreaking study proves a botanical compound enhances protein absorption, leading to measurable gains in muscle strength and mass, especially for older adults.

A new platform is launching to connect pharma companies directly with 70+ global regulators, promising to slash approval times and speed patient access.

The homesite developer declared a $0.76 quarterly dividend, showcasing a resilient model that thrives by offering builders an asset-light land strategy.

Endevica Bio launches Kalohexis, a new biotech aiming to disrupt the obesity market with a drug that resets the body's 'metabolic thermostat'.

A new biotech spins out with a novel drug class aiming to provide healthier, more durable weight loss and combat cancer-related wasting syndrome.

Ultralytics, creator of the popular YOLO models, launches a new platform to streamline the chaotic world of computer vision development from start to finish.

Billionaire-backed PEAK6 is paying founders a $100K salary to build fintech unicorns in Austin, challenging the traditional startup accelerator model.

A Wisconsin RIA's launch was nearly derailed by its tech choice. Their story of a mid-transition pivot reveals a crucial lesson for all advisors.

Atlanta lawyer Anne Tyler Hall lands on Inc.'s prestigious list for saving companies millions and mastering complex employee benefits law.

Celebrating 80 years, Aveeno renews its foundational ties with Mayo Clinic, launching a new era of oat science research for compromised skin.

Eve Air Mobility, Alt Air, and Skyports team up to launch eVTOL services in NSW and Queensland, with an eye on the Brisbane 2032 Olympic Games.

As Capricor prepares its Q4 earnings call, all eyes are on its DMD drug Deramiocel's FDA path, financial health, and next-gen exosome technology.

With the appointment of Tim McCracken as CRO, SOLUM America unifies its sales strategy to capture the booming North American electronic shelf label market.

Corteva Agriscience is splitting into two focused powerhouses for seeds and crop protection. Will this bold move unlock new value or create new risks?

The Bloomberg 500 adds 11 tech-heavy firms like Nebius Group and ASTS, signaling a major shift in market leadership driven by AI and digital infrastructure.

Despite a full-year GAAP loss, AFC declares a dividend and shifts its strategy post-BDC conversion. Can it resolve legacy loans and find new growth?

With 14% growth, strategic acquisitions, and major AI advancements, Real Chemistry is redefining healthcare commercialization on its 25th anniversary.